Correction to Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions

IF 6.3 2区医学 Q1 PHARMACOLOGY & PHARMACY Clinical Pharmacology & Therapeutics Pub Date : 2024-11-15 DOI:10.1002/cpt.3453

{"title":"Correction to Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions","authors":"","doi":"10.1002/cpt.3453","DOIUrl":null,"url":null,"abstract":"Sola-Morales, O. et al. Effectively leveraging RWD for external controls: a systematic literature review of regulatory and HTA decisions. Clin. Pharmacol. Ther. 114, 325–355 (2023). https://doi.org/10.1002/cpt.2914The following adjustments should be made to the text:\n \n References\n 124. NICE. Asfotase alfa for treating paediatric-onset hypophosphatasia <https://www.nice.org.uk/guidance/hst6> (2017). Accessed 24 May, 2024.125. NICE. Onasemnogene abeparvovec for treating spinal muscular atrophy https://www.nice.org.uk/guidance/hst15 (2021). Accessed 24 May, 2024.126. GBA. Certinib. Supporting Grounds <https://www.g-ba.de/downloads/40-268-3496/2015-12-17_AM-RL-XII_Ceritinib_2015-07-01-D-171_TrG.pdf> (2015). Accessed 24 May, 2024.127. GBA. Efmoroctocog alfa. Supporting Grounds <https://www.g-ba.de/downloads/40-268-3824/2016-06-16_AM-RL-XII_Efmoroctocog-alfa_D-195_TrG.pdf> (2016). Accessed 24 May, 2024.128. GBA. Nivolumab. Supporting Grounds <https://www.g-ba.de/downloads/40-268-4426/2017-06-15_AM-RL-XII_Nivolumab_D-267_TrG.pdf> (2017). Accessed 12 August, 2024.129. NICE. Vismodegib for treating basal cell carcinoma <https://www.nice.org.uk/guidance/ta489> (2017). Accessed 24 May, 2024.We hope that these updates improve the interpretation and clarity of this manuscript.","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":"117 1","pages":"289-308"},"PeriodicalIF":6.3000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.3453","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpt.3453","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Sola-Morales, O. et al. Effectively leveraging RWD for external controls: a systematic literature review of regulatory and HTA decisions. Clin. Pharmacol. Ther. 114, 325–355 (2023). https://doi.org/10.1002/cpt.2914

The following adjustments should be made to the text:

References

124. NICE. Asfotase alfa for treating paediatric-onset hypophosphatasia <https://www.nice.org.uk/guidance/hst6> (2017). Accessed 24 May, 2024.

125. NICE. Onasemnogene abeparvovec for treating spinal muscular atrophy https://www.nice.org.uk/guidance/hst15 (2021). Accessed 24 May, 2024.

126. GBA. Certinib. Supporting Grounds <https://www.g-ba.de/downloads/40-268-3496/2015-12-17_AM-RL-XII_Ceritinib_2015-07-01-D-171_TrG.pdf> (2015). Accessed 24 May, 2024.

127. GBA. Efmoroctocog alfa. Supporting Grounds <https://www.g-ba.de/downloads/40-268-3824/2016-06-16_AM-RL-XII_Efmoroctocog-alfa_D-195_TrG.pdf> (2016). Accessed 24 May, 2024.

128. GBA. Nivolumab. Supporting Grounds <https://www.g-ba.de/downloads/40-268-4426/2017-06-15_AM-RL-XII_Nivolumab_D-267_TrG.pdf> (2017). Accessed 12 August, 2024.

129. NICE. Vismodegib for treating basal cell carcinoma <https://www.nice.org.uk/guidance/ta489> (2017). Accessed 24 May, 2024.

We hope that these updates improve the interpretation and clarity of this manuscript.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

校正有效利用 RWD 进行外部控制：关于监管和 HTA 决策的系统文献综述》。

Sola-Morales， O.等。有效地利用RWD进行外部控制：对监管和HTA决策的系统文献综述。中国。杂志。再114,325-355（2023）。https://doi.org/10.1002/cpt.2914The对案文应作下列调整：参考文献124。好了。Asfotase alfa治疗儿科低磷酸症<；https://www.nice.org.uk/guidance/hst6>；(2017)。2015年5月24日访问。好了。Onasemnogene abeparvovec用于治疗脊髓性肌萎缩https://www.nice.org.uk/guidance/hst15（2021）。于2024年5月24日访问。GBA。Certinib。支持理由<；https://www.g-ba.de/downloads/40-268-3496/2015-12-17_AM-RL-XII_Ceritinib_2015-07-01-D-171_TrG.pdf>；(2015)。2012年5月24日GBA。Efmoroctocog阿尔法。支持理由<；https://www.g-ba.de/downloads/40-268-3824/2016-06-16_AM-RL-XII_Efmoroctocog-alfa_D-195_TrG.pdf>；(2016)。2024.128年5月24日访问。GBA。Nivolumab。支持理由<；https://www.g-ba.de/downloads/40-268-4426/2017-06-15_AM-RL-XII_Nivolumab_D-267_TrG.pdf>；(2017)。访问日期：2024.8月12日。好了。维莫替吉治疗基底细胞癌<；https://www.nice.org.uk/guidance/ta489>；(2017)。获得于2024年5月24日。我们希望这些更新能改善这篇手稿的解释和清晰度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Pharmacology & Therapeutics 医学-药学

CiteScore

12.70

自引率

7.50%

发文量

290

审稿时长

2 months

期刊介绍： Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original Articles in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.